More adverse dental outcomes seen with sublingual buprenorphine\/naloxone compared with use of transdermal buprenorphine or oral naltrexone<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Dec. 16, 2022 (HealthDay News) — There is a higher risk for adverse dental outcomes associated with sublingual buprenorphine\/naloxone compared with transdermal buprenorphine or oral naltrexone, according to a research letter published in the Dec. 13 issue of the Journal of the American Medical Association<\/em>.<\/p>\n Mahyar Etminan, Pharm.D., from the University of British Columbia in Vancouver, Canada, and colleagues used the PharMetrics database to examine the association between sublingual buprenorphine\/naloxone and dental adverse events. The analysis included 21,404 new users of sublingual buprenorphine\/naloxone, 5,385 users of transdermal buprenorphine, and 6,616 users of oral naltrexone.<\/p>\n The researchers found that the incidence of any dental adverse event was 21.6 per 1,000 person-years with sublingual buprenorphine\/naloxone, 12.2 per 1,000 person-years with transdermal buprenorphine, and 10.9 per 1,000 person-years with oral naltrexone. The risk for dental adverse events was higher for sublingual buprenorphine\/naloxone versus both transdermal buprenorphine (adjusted hazard ratio [aHR], 1.42) and oral naltrexone (aHR, 1.67). Similarly, the incidence of dental caries or tooth loss was 8.2 per 1,000 person-years with sublingual buprenorphine\/naloxone, 3.5 per 1,000 person-years with transdermal buprenorphine, and 3.8 per 1,000 person-years with oral naltrexone. A higher risk for dental caries or tooth loss was seen for sublingual buprenorphine\/naloxone versus both transdermal buprenorphine (aHR, 1.57) and oral naltrexone (aHR, 1.71).<\/p>\n “Clinicians might consider drugs other than sublingual buprenorphine\/naloxone in patients with previous dental problems,” the authors write. “These patients might also benefit from regular oral health examinations by their dentist.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n